Today, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) launches the report “50 Years of Global Health Progress”, which traces global health progress over the past 50 years and also looks forward to challenges and opportunities for the next 50 years.
The report, authored by SustainAbility, marks IFPMA’s 50-year anniversary, and launches on the occasion of the 71st World Health Assembly on 23rd May in Geneva.
The report reviews the collaborative role the research-based biopharmaceutical industry has played not only to deliver prevention and treatment, but to strengthen health systems around the world.
The report reviews the collaborative role the research-based biopharmaceutical industry has played not only to deliver prevention and treatment, but to strengthen health systems around the world. This includes some of the industry’s major scientific advances, as well as acknowledging challenges the industry faces and areas of unfinished business. The industry’s track record of partnerships over recent decades demonstrates what can be achieved by uniting governments, civil society and business. The report concludes with a commitment to continue to innovate and partner with a shared goal to deliver better health for everyone, everywhere.
Advances in both prevention and treatment of disease have transformed healthcare. Vaccines are widely recognized as the simplest, most cost-effective way to save lives. HIV/AIDS, once fatal, can now be treated as can many cancers. Cardiovascular sufferers benefit from simple-one-a-day solutions. We can now cure Hepatitis C.
“The R&D-based biopharmaceutical industry plays a vital role in human health and prosperity delivering not only vital medicines and vaccines but skills and expertise. In looking backwards and forwards, this report ensures we’re learning from the past and making the future the cause of the present.” – Rob Cameron, Chief Executive, SustainAbility
Alongside innovation, global health partnerships included in the 1970s, the Expanded Program on Immunization and, in the 1980s, the polio eradication and smallpox initiatives. These have been followed by partnerships as diverse as DNDi, MMV, Global Fund for AIDS, TB and Malaria, GAVI, the Vaccine Alliance and, more recently, CEPI or Access Accelerated. Partnerships are now the norm and the Sustainable Developments Goals (SDGs) serve to galvanize greater collaboration to confront new and remaining challenges as many people still lack access to essential health services.
“The next 50 years will be about further delivering on our purpose: putting patients first to deliver better health for everyone, everywhere.” – Thomas Cueni, Director General, IFPMA
About the IFPMA
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees discover, develop, and deliver medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.